drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB05294 | DB06637 | 1,069 | 1,109 | [
"DDInter1917",
"DDInter468"
] | Vandetanib | Dalfampridine | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010. | Moderate | 1 | [
[
[
1069,
24,
1109
]
],
[
[
1069,
21,
28880
],
[
28880,
60,
1109
]
],
[
[
1069,
25,
1619
],
[
1619,
63,
1109
]
],
[
[
1069,
63,
1645
],
[
... | [
[
[
"Vandetanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfampridine"
]
],
[
[
"Vandetanib",
"{u} (Compound) causes {v} (Side Effect)",
"Angiopathy"
],
[
"Angiopathy",
"{u} (Side Effect) is... | Vandetanib (Compound) causes Angiopathy (Side Effect) and Angiopathy (Side Effect) is caused by Dalfampridine (Compound)
Vandetanib may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Dalfampridine
Vande... |
DB00529 | DB01177 | 789 | 77 | [
"DDInter779",
"DDInter904"
] | Foscarnet | Idarubicin | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Moderate | 1 | [
[
[
789,
24,
77
]
],
[
[
789,
21,
28987
],
[
28987,
60,
77
]
],
[
[
789,
23,
112
],
[
112,
23,
77
]
],
[
[
789,
24,
823
],
[
823,
63... | [
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Foscarnet",
"{u} (Compound) causes {v} (Side Effect)",
"Chills"
],
[
"Chills",
"{u} (Side Effect) is caused by {v... | Foscarnet (Compound) causes Chills (Side Effect) and Chills (Side Effect) is caused by Idarubicin (Compound)
Foscarnet may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Idarubicin
Fo... |
DB00208 | DB01320 | 1,018 | 651 | [
"DDInter1804",
"DDInter783"
] | Ticlopidine | Fosphenytoin | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Moderate | 1 | [
[
[
1018,
24,
651
]
],
[
[
1018,
24,
362
],
[
362,
1,
651
]
],
[
[
1018,
6,
6017
],
[
6017,
45,
651
]
],
[
[
1018,
21,
28784
],
[
28784,
... | [
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[... | Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
Ticlopidine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Fosphenytoin (Compound)
Ticlopidine (Compound) causes Thrombocytopenia (Side Effect) a... |
DB01192 | DB06209 | 560 | 256 | [
"DDInter1372",
"DDInter1508"
] | Oxymorphone | Prasugrel | An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). O... | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Moderate | 1 | [
[
[
560,
24,
256
]
],
[
[
560,
6,
8374
],
[
8374,
45,
256
]
],
[
[
560,
21,
28681
],
[
28681,
60,
256
]
],
[
[
560,
63,
752
],
[
752,
... | [
[
[
"Oxymorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Oxymorphone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Oxymorphone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Prasugrel (Compound)
Oxymorphone (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Prasugrel (Compound)
Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Cime... |
DB00668 | DB01618 | 874 | 776 | [
"DDInter652",
"DDInter1239"
] | Epinephrine | Molindone | Epinephrine, also known as _adrenaline_, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Though it has long been used in the treatment of hypersensitivity reactions, epinephrine in the auto-injector form (EpiPen) has been avail... | An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. It has only low to mo... | Moderate | 1 | [
[
[
874,
24,
776
]
],
[
[
874,
6,
5372
],
[
5372,
45,
776
]
],
[
[
874,
7,
4622
],
[
4622,
46,
776
]
],
[
[
874,
21,
28691
],
[
28691,
... | [
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Molindone"
]
],
[
[
"Epinephrine",
"{u} (Compound) binds {v} (Gene)",
"ADRA2A"
],
[
"ADRA2A",
"{u} (Gene) is bound by {v} (Compound)"... | Epinephrine (Compound) binds ADRA2A (Gene) and ADRA2A (Gene) is bound by Molindone (Compound)
Epinephrine (Compound) upregulates PRKCD (Gene) and PRKCD (Gene) is upregulated by Molindone (Compound)
Epinephrine (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Molindone (Compound)
Epin... |
DB00016 | DB00691 | 787 | 1,058 | [
"DDInter671",
"DDInter1237"
] | Erythropoietin | Moexipril | Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow [FDA Label]. Epoetin alfa (Epoge) was developed by Amgen Inc. in 1983 as the first rhEPO commerc... | Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney prob... | Minor | 0 | [
[
[
787,
23,
1058
]
],
[
[
787,
23,
1638
],
[
1638,
1,
1058
]
],
[
[
787,
23,
954
],
[
954,
40,
1058
]
],
[
[
787,
23,
1638
],
[
1638,
... | [
[
[
"Erythropoietin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Moexipril"
]
],
[
[
"Erythropoietin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trandolapril"
],
... | Erythropoietin may cause a minor interaction that can limit clinical effects when taken with Trandolapril and Trandolapril (Compound) resembles Moexipril (Compound)
Erythropoietin may cause a minor interaction that can limit clinical effects when taken with Quinapril and Quinapril (Compound) resembles Moexipril (Compou... |
DB00014 | DB12332 | 521 | 1,619 | [
"DDInter839",
"DDInter1626"
] | Goserelin | Rucaparib | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
521,
24,
1619
]
],
[
[
521,
23,
112
],
[
112,
23,
1619
]
],
[
[
521,
24,
87
],
[
87,
24,
1619
]
],
[
[
521,
24,
180
],
[
180,
63... | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Goserelin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Goserelin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Amoxapine and Amoxapin... |
DB01234 | DB08875 | 1,220 | 1,618 | [
"DDInter513",
"DDInter262"
] | Dexamethasone | Cabozantinib | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Moderate | 1 | [
[
[
1220,
24,
1618
]
],
[
[
1220,
24,
1135
],
[
1135,
62,
1618
]
],
[
[
1220,
63,
723
],
[
723,
24,
1618
]
],
[
[
1220,
24,
384
],
[
384,
... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
... | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Ap... |
DB00424 | DB01242 | 19 | 1,237 | [
"DDInter896",
"DDInter410"
] | Hyoscyamine | Clomipramine | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Moderate | 1 | [
[
[
19,
24,
1237
]
],
[
[
19,
24,
684
],
[
684,
1,
1237
]
],
[
[
19,
24,
272
],
[
272,
24,
1237
]
],
[
[
19,
24,
146
],
[
146,
40,
... | [
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thioridazine"
],
... | Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Thioridazine and Thioridazine (Compound) resembles Clomipramine (Compound)
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate in... |
DB04951 | DB06414 | 187 | 655 | [
"DDInter1477",
"DDInter703"
] | Pirfenidone | Etravirine | Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is pro... | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Moderate | 1 | [
[
[
187,
24,
655
]
],
[
[
187,
62,
168
],
[
168,
23,
655
]
],
[
[
187,
63,
300
],
[
300,
24,
655
]
],
[
[
187,
25,
868
],
[
868,
63,... | [
[
[
"Pirfenidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Pirfenidone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
... | Pirfenidone may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Etravirine
Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Letrozole and Letrozole... |
DB00023 | DB04951 | 305 | 187 | [
"DDInter127",
"DDInter1477"
] | Asparaginase Escherichia coli | Pirfenidone | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is pro... | Moderate | 1 | [
[
[
305,
24,
187
]
],
[
[
305,
24,
168
],
[
168,
23,
187
]
],
[
[
305,
24,
463
],
[
463,
24,
187
]
],
[
[
305,
24,
996
],
[
996,
63,... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pirfenidone"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Pirfenidone
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases ... |
DB00816 | DB04844 | 1,674 | 843 | [
"DDInter1346",
"DDInter1778"
] | Orciprenaline | Tetrabenazine | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Moderate | 1 | [
[
[
1674,
24,
843
]
],
[
[
1674,
21,
28698
],
[
28698,
60,
843
]
],
[
[
1674,
63,
1555
],
[
1555,
24,
843
]
],
[
[
1674,
24,
823
],
[
823,... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Orciprenaline",
"{u} (Compound) causes {v} (Side Effect)",
"Insomnia"
],
[
"Insomnia",
"{u} (Side Effect) ... | Orciprenaline (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Tetrabenazine (Compound)
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB09488 | DB11642 | 103 | 938 | [
"DDInter23",
"DDInter1480"
] | Acrivastine | Pitolisant | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema,... | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnag... | Moderate | 1 | [
[
[
103,
24,
938
]
],
[
[
103,
63,
1233
],
[
1233,
24,
938
]
],
[
[
103,
63,
1233
],
[
1233,
24,
820
],
[
820,
24,
938
]
],
[
[
103,
... | [
[
[
"Acrivastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Acrivastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triprolidine"
],
... | Acrivastine may cause a moderate interaction that could exacerbate diseases when taken with Triprolidine and Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Acrivastine may cause a moderate interaction that could exacerbate diseases when taken with Triprolidine an... |
DB00927 | DB01263 | 1,559 | 859 | [
"DDInter712",
"DDInter1494"
] | Famotidine | Posaconazole | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Moderate | 1 | [
[
[
1559,
24,
859
]
],
[
[
1559,
21,
28762
],
[
28762,
60,
859
]
],
[
[
1559,
62,
112
],
[
112,
23,
859
]
],
[
[
1559,
23,
286
],
[
286,
... | [
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Famotidine",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caus... | Famotidine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Posaconazole (Compound)
Famotidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Posac... |
DB00289 | DB00916 | 847 | 112 | [
"DDInter132",
"DDInter1202"
] | Atomoxetine | Metronidazole | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve develop... | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Minor | 0 | [
[
[
847,
23,
112
]
],
[
[
847,
6,
8374
],
[
8374,
45,
112
]
],
[
[
847,
21,
28692
],
[
28692,
60,
112
]
],
[
[
847,
63,
618
],
[
618,
... | [
[
[
"Atomoxetine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
]
],
[
[
"Atomoxetine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Atomoxetine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Metronidazole (Compound)
Atomoxetine (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Metronidazole (Compound)
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB01114 | DB01452 | 272 | 993 | [
"DDInter362",
"DDInter532"
] | Chlorpheniramine | Diamorphine | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Diamorphine (heroin) is a narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed) Internationally, diamorphine is ... | Moderate | 1 | [
[
[
272,
24,
993
]
],
[
[
272,
63,
421
],
[
421,
40,
993
]
],
[
[
272,
63,
475
],
[
475,
25,
993
]
],
[
[
272,
63,
13
],
[
13,
24,
... | [
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diamorphine"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydromorphone"... | Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Diamorphine (Compound)
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life thr... |
DB00390 | DB08865 | 1,252 | 1,593 | [
"DDInter554",
"DDInter448"
] | Digoxin | Crizotinib | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
1252,
24,
1593
]
],
[
[
1252,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
1252,
7,
5295
],
[
5295,
45,
1593
]
],
[
[
1252,
18,
2035
],
[
2035... | [
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Digoxin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Digoxin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Digoxin (Compound) upregulates CDK7 (Gene) and CDK7 (Gene) is bound by Crizotinib (Compound)
Digoxin (Compound) downregulates IRAK1 (Gene) and IRAK1 (Gene) is bound by Crizotinib (Compound)
Digoxin (Compound) upregulates COL11A1 ... |
DB00637 | DB00745 | 1,557 | 307 | [
"DDInter128",
"DDInter1236"
] | Astemizole | Modafinil | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron ac... | Minor | 0 | [
[
[
1557,
23,
307
]
],
[
[
1557,
40,
704
],
[
704,
40,
307
]
],
[
[
1557,
24,
675
],
[
675,
40,
307
]
],
[
[
1557,
63,
847
],
[
847,
... | [
[
[
"Astemizole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
]
],
[
[
"Astemizole",
"{u} (Compound) resembles {v} (Compound)",
"Fentanyl"
],
[
"Fentanyl",
"{u} (Compound) resembles {v} (... | Astemizole (Compound) resembles Fentanyl (Compound) and Fentanyl (Compound) resembles Modafinil (Compound)
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene (Compound) resembles Modafinil (Compound)
Astemizole may cause a moderate intera... |
DB00912 | DB08880 | 473 | 1,510 | [
"DDInter1581",
"DDInter1771"
] | Repaglinide | Teriflunomide | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Moderate | 1 | [
[
[
473,
24,
1510
]
],
[
[
473,
24,
129
],
[
129,
63,
1510
]
],
[
[
473,
63,
303
],
[
303,
24,
1510
]
],
[
[
473,
24,
697
],
[
697,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Medroxyproge... |
DB00748 | DB01081 | 662 | 1,688 | [
"DDInter297",
"DDInter571"
] | Carbinoxamine | Diphenoxylate | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | A meperidine congener used as an antidiarrheal, usually in combination with atropine. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity. This medication is classified as a Schedule V under the Controlled Subst... | Moderate | 1 | [
[
[
662,
24,
1688
]
],
[
[
662,
63,
576
],
[
576,
1,
1688
]
],
[
[
662,
63,
194
],
[
194,
40,
1688
]
],
[
[
662,
24,
262
],
[
262,
4... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenoxylate"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
],
... | Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone (Compound) resembles Diphenoxylate (Compound)
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Darifenacin and Darifenacin (Compound) resembles Diphenoxylate... |
DB00502 | DB00662 | 1,300 | 717 | [
"DDInter853",
"DDInter1873"
] | Haloperidol | Trimethobenzamide | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Moderate | 1 | [
[
[
1300,
24,
717
]
],
[
[
1300,
25,
1425
],
[
1425,
40,
717
]
],
[
[
1300,
21,
28762
],
[
28762,
60,
717
]
],
[
[
1300,
63,
1594
],
[
159... | [
[
[
"Haloperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Haloperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
],
[
"Ci... | Haloperidol may lead to a major life threatening interaction when taken with Cisapride and Cisapride (Compound) resembles Trimethobenzamide (Compound)
Haloperidol (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Trimethobenzamide (Compound)
Haloperidol may cause a moderate interaction th... |
DB11732 | DB12015 | 1,097 | 1,033 | [
"DDInter1027",
"DDInter53"
] | Lasmiditan | Alpelisib | Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have se... | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
1097,
24,
1033
]
],
[
[
1097,
63,
1135
],
[
1135,
23,
1033
]
],
[
[
1097,
24,
738
],
[
738,
24,
1033
]
],
[
[
1097,
63,
1510
],
[
1510... | [
[
[
"Lasmiditan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Lasmiditan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
... | Lasmiditan may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Alpelisib
Lasmiditan may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib ma... |
DB00331 | DB06016 | 1,645 | 1,508 | [
"DDInter1164",
"DDInter300"
] | Metformin | Cariprazine | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | Moderate | 1 | [
[
[
1645,
24,
1508
]
],
[
[
1645,
24,
1593
],
[
1593,
63,
1508
]
],
[
[
1645,
63,
176
],
[
176,
24,
1508
]
],
[
[
1645,
24,
1411
],
[
1411... | [
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
... | Metformin may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and I... |
DB00514 | DB00532 | 506 | 208 | [
"DDInter527",
"DDInter1152"
] | Dextromethorphan | Mephenytoin | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subuni... | Moderate | 1 | [
[
[
506,
24,
208
]
],
[
[
506,
63,
475
],
[
475,
24,
208
]
],
[
[
506,
24,
1219
],
[
1219,
63,
208
]
],
[
[
506,
25,
222
],
[
222,
6... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephenytoin"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
... | Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Mephenytoin
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Azatadine an... |
DB01041 | DB11915 | 770 | 1,293 | [
"DDInter1789",
"DDInter1909"
] | Thalidomide | Valbenazine | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine recept... | Moderate | 1 | [
[
[
770,
24,
1293
]
],
[
[
770,
63,
112
],
[
112,
23,
1293
]
],
[
[
770,
25,
710
],
[
710,
63,
1293
]
],
[
[
770,
63,
521
],
[
521,
... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Valbenazine
Thalidomide may lead to a major life threatening interaction when taken with Binimetinib and Binimetinib m... |
DB00370 | DB06694 | 1,251 | 31 | [
"DDInter1230",
"DDInter1952"
] | Mirtazapine | Xylometazoline (nasal) | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | Xylometazoline is an alkylbenzene. | Moderate | 1 | [
[
[
1251,
24,
31
]
],
[
[
1251,
6,
5214
],
[
5214,
45,
31
]
],
[
[
1251,
24,
144
],
[
144,
63,
31
]
],
[
[
1251,
24,
1148
],
[
1148,
... | [
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Xylometazoline"
]
],
[
[
"Mirtazapine",
"{u} (Compound) binds {v} (Gene)",
"ADRA1A"
],
[
"ADRA1A",
"{u} (Gene) is bound by {v} (Compo... | Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Xylometazoline
Mirtazapine (Compound) binds ADRA1A (Gene) and ADRA1A (Gene) is bound by Xylometazoline (Compound)
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodate... |
DB00765 | DB01114 | 1,266 | 272 | [
"DDInter1205",
"DDInter362"
] | Metyrosine | Chlorpheniramine | An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed) | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
1266,
24,
272
]
],
[
[
1266,
24,
849
],
[
849,
63,
272
]
],
[
[
1266,
63,
128
],
[
128,
24,
272
]
],
[
[
1266,
21,
28779
],
[
28779,
... | [
[
[
"Metyrosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Metyrosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
... | Metyrosine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Metyrosine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniram... |
DB00603 | DB09045 | 303 | 52 | [
"DDInter1137",
"DDInter607"
] | Medroxyprogesterone acetate | Dulaglutide | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
303,
24,
52
]
],
[
[
303,
24,
170
],
[
170,
23,
52
]
],
[
[
303,
24,
609
],
[
609,
24,
52
]
],
[
[
303,
40,
989
],
[
989,
24,
... | [
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",... | Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases wh... |
DB08865 | DB12245 | 1,593 | 823 | [
"DDInter448",
"DDInter1863"
] | Crizotinib | Triclabendazole | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Major | 2 | [
[
[
1593,
25,
823
]
],
[
[
1593,
62,
1247
],
[
1247,
23,
823
]
],
[
[
1593,
63,
112
],
[
112,
23,
823
]
],
[
[
1593,
25,
1612
],
[
1612,
... | [
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Crizotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"S... | Crizotinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Metronid... |
DB09564 | DB15093 | 1,296 | 1,654 | [
"DDInter930",
"DDInter1698"
] | Insulin degludec | Somapacitan | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
1296,
24,
1654
]
],
[
[
1296,
63,
168
],
[
168,
23,
1654
]
],
[
[
1296,
24,
433
],
[
433,
24,
1654
]
],
[
[
1296,
63,
135
],
[
135,
... | [
[
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
... | Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflo... |
DB00957 | DB06674 | 873 | 908 | [
"DDInter1314",
"DDInter837"
] | Norgestimate | Golimumab | Norgestimate was first described in the literature in 1977. It was developed by Ortho Pharmaceutical Corporation as part of an effort to develop new hormonal contraceptives with reduced adverse effects. It is commonly formulated with [ethinylestradiol] as a combined oral contraceptive that can also be used to treat mod... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Moderate | 1 | [
[
[
873,
24,
908
]
],
[
[
873,
40,
1197
],
[
1197,
24,
908
]
],
[
[
873,
23,
14
],
[
14,
24,
908
]
],
[
[
873,
63,
58
],
[
58,
24,
... | [
[
[
"Norgestimate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
]
],
[
[
"Norgestimate",
"{u} (Compound) resembles {v} (Compound)",
"Norethisterone"
],
[
"Norethisterone",
"{u} may caus... | Norgestimate (Compound) resembles Norethisterone (Compound) and Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Norgestimate may cause a minor interaction that can limit clinical effects when taken with Rosuvastatin and Rosuvastatin may cause a moderate interacti... |
DB00761 | DB00814 | 1,621 | 1,171 | [
"DDInter1497",
"DDInter1143"
] | Potassium chloride | Meloxicam | A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives. The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium p... | Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is ... | Moderate | 1 | [
[
[
1621,
24,
1171
]
],
[
[
1621,
63,
1027
],
[
1027,
40,
1171
]
],
[
[
1621,
21,
28750
],
[
28750,
60,
1171
]
],
[
[
1621,
63,
1274
],
[
... | [
[
[
"Potassium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meloxicam"
]
],
[
[
"Potassium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Piroxicam"
... | Potassium chloride may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam and Piroxicam (Compound) resembles Meloxicam (Compound)
Potassium chloride (Compound) causes Abdominal discomfort (Side Effect) and Abdominal discomfort (Side Effect) is caused by Meloxicam (Compound)
Potassium ... |
DB11837 | DB14975 | 1,297 | 988 | [
"DDInter1351",
"DDInter1949"
] | Osilodrostat | Voxelotor | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications aris... | Moderate | 1 | [
[
[
1297,
24,
988
]
],
[
[
1297,
62,
222
],
[
222,
23,
988
]
],
[
[
1297,
23,
466
],
[
466,
23,
988
]
],
[
[
1297,
63,
254
],
[
254,
... | [
[
[
"Osilodrostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voxelotor"
]
],
[
[
"Osilodrostat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
... | Osilodrostat may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Voxelotor
Osilodrostat may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darol... |
DB00731 | DB00738 | 1,144 | 485 | [
"DDInter1269",
"DDInter1420"
] | Nateglinide | Pentamidine | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Moderate | 1 | [
[
[
1144,
24,
485
]
],
[
[
1144,
6,
12523
],
[
12523,
45,
485
]
],
[
[
1144,
21,
29093
],
[
29093,
60,
485
]
],
[
[
1144,
24,
1247
],
[
12... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
]
],
[
[
"Nateglinide",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound... | Nateglinide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pentamidine (Compound)
Nateglinide (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Pentamidine (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole a... |
DB00295 | DB00593 | 475 | 1,464 | [
"DDInter1244",
"DDInter695"
] | Morphine | Ethosuximide | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. | Moderate | 1 | [
[
[
475,
24,
1464
]
],
[
[
475,
6,
8374
],
[
8374,
45,
1464
]
],
[
[
475,
21,
28723
],
[
28723,
60,
1464
]
],
[
[
475,
24,
401
],
[
401,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethosuximide"
]
],
[
[
"Morphine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Morphine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ethosuximide (Compound)
Morphine (Compound) causes Malnutrition (Side Effect) and Malnutrition (Side Effect) is caused by Ethosuximide (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine an... |
DB00427 | DB01215 | 1,233 | 1,418 | [
"DDInter1879",
"DDInter677"
] | Triprolidine | Estazolam | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam. | Moderate | 1 | [
[
[
1233,
24,
1418
]
],
[
[
1233,
63,
523
],
[
523,
1,
1418
]
],
[
[
1233,
24,
1216
],
[
1216,
40,
1418
]
],
[
[
1233,
63,
905
],
[
905,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estazolam"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alprazolam"
],
[... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Alprazolam and Alprazolam (Compound) resembles Estazolam (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Estazolam (Compound... |
DB00570 | DB11932 | 147 | 327 | [
"DDInter1936",
"DDInter3"
] | Vinblastine | Abametapir (topical) | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Abametapir is a member of bipyridines. | Moderate | 1 | [
[
[
147,
24,
327
]
],
[
[
147,
63,
168
],
[
168,
24,
327
]
],
[
[
147,
24,
283
],
[
283,
63,
327
]
],
[
[
147,
24,
309
],
[
309,
24,... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Vinblast... |
DB00023 | DB09045 | 305 | 52 | [
"DDInter127",
"DDInter607"
] | Asparaginase Escherichia coli | Dulaglutide | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
305,
24,
52
]
],
[
[
305,
24,
170
],
[
170,
23,
52
]
],
[
[
305,
24,
609
],
[
609,
24,
52
]
],
[
[
305,
24,
517
],
[
517,
63,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate disease... |
DB01024 | DB06643 | 1,096 | 1,136 | [
"DDInter1252",
"DDInter500"
] | Mycophenolic acid | Denosumab | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Moderate | 1 | [
[
[
1096,
24,
1136
]
],
[
[
1096,
25,
1377
],
[
1377,
24,
1136
]
],
[
[
1096,
25,
1510
],
[
1510,
63,
1136
]
],
[
[
1096,
63,
629
],
[
629... | [
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Mycophenolic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
... | Mycophenolic acid may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Mycophenolic acid may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may ... |
DB00476 | DB11703 | 109 | 405 | [
"DDInter608",
"DDInter9"
] | Duloxetine | Acalabrutinib | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Moderate | 1 | [
[
[
109,
24,
405
]
],
[
[
109,
23,
1384
],
[
1384,
24,
405
]
],
[
[
109,
40,
758
],
[
758,
24,
405
]
],
[
[
109,
24,
1297
],
[
1297,
... | [
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Duloxetine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
],
[
... | Duloxetine may cause a minor interaction that can limit clinical effects when taken with Magaldrate and Magaldrate may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Duloxetine (Compound) resembles Fluoxetine (Compound) and Fluoxetine may cause a moderate interaction that coul... |
DB00604 | DB00679 | 1,425 | 684 | [
"DDInter385",
"DDInter1796"
] | Cisapride | Thioridazine | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Major | 2 | [
[
[
1425,
25,
684
]
],
[
[
1425,
25,
1237
],
[
1237,
40,
684
]
],
[
[
1425,
64,
216
],
[
216,
1,
684
]
],
[
[
1425,
25,
1630
],
[
1630,
... | [
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clomipramine"
],
[
"Clomipramine",
"{... | Cisapride may lead to a major life threatening interaction when taken with Clomipramine and Clomipramine (Compound) resembles Thioridazine (Compound)
Cisapride may lead to a major life threatening interaction when taken with Chlorpromazine and Chlorpromazine (Compound) resembles Thioridazine (Compound)
Cisapride may le... |
DB00794 | DB01234 | 759 | 1,220 | [
"DDInter1521",
"DDInter513"
] | Primidone | Dexamethasone | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
759,
24,
1220
]
],
[
[
759,
63,
870
],
[
870,
1,
1220
]
],
[
[
759,
63,
175
],
[
175,
40,
1220
]
],
[
[
759,
24,
1486
],
[
1486,
... | [
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
... | Primidone may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Dexam... |
DB00284 | DB12267 | 1,647 | 1,476 | [
"DDInter11",
"DDInter233"
] | Acarbose | Brigatinib | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are r... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
1647,
24,
1476
]
],
[
[
1647,
63,
168
],
[
168,
23,
1476
]
],
[
[
1647,
24,
629
],
[
629,
24,
1476
]
],
[
[
1647,
23,
135
],
[
135,
... | [
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may... |
DB11718 | DB11853 | 927 | 230 | [
"DDInter640",
"DDInter1577"
] | Encorafenib | Relugolix | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under th... | Moderate | 1 | [
[
[
927,
24,
230
]
],
[
[
927,
64,
129
],
[
129,
23,
230
]
],
[
[
927,
63,
1094
],
[
1094,
23,
230
]
],
[
[
927,
62,
112
],
[
112,
2... | [
[
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Encorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalut... | Encorafenib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin and Metreleptin may c... |
DB00290 | DB00438 | 329 | 149 | [
"DDInter219",
"DDInter330"
] | Bleomycin | Ceftazidime | A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. | Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as "penicillin-binding proteins" (PBPs). β-lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of esse... | Moderate | 1 | [
[
[
329,
24,
149
]
],
[
[
329,
21,
29196
],
[
29196,
60,
149
]
],
[
[
329,
24,
450
],
[
450,
63,
149
]
],
[
[
329,
21,
29196
],
[
29196,
... | [
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ceftazidime"
]
],
[
[
"Bleomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Paraesthesia"
],
[
"Paraesthesia",
"{u} (Side Effect) is... | Bleomycin (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Ceftazidime (Compound)
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when t... |
DB00252 | DB00620 | 362 | 175 | [
"DDInter1460",
"DDInter1855"
] | Phenytoin | Triamcinolone | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Moderate | 1 | [
[
[
362,
24,
175
]
],
[
[
362,
24,
1573
],
[
1573,
1,
175
]
],
[
[
362,
6,
8374
],
[
8374,
45,
175
]
],
[
[
362,
7,
6858
],
[
6858,
... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
... | Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) resembles Triamcinolone (Compound)
Phenytoin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Triamcinolone (Compound)
Phenytoin (Compound) upregulates LPL (Gene) and LPL (Gene) is ... |
DB05528 | DB06603 | 1,070 | 39 | [
"DDInter1228",
"DDInter1387"
] | Mipomersen | Panobinostat | Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. M... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
1070,
25,
39
]
],
[
[
1070,
64,
912
],
[
912,
24,
39
]
],
[
[
1070,
25,
1478
],
[
1478,
63,
39
]
],
[
[
1070,
25,
594
],
[
594,
... | [
[
[
"Mipomersen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Mipomersen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta... | Mipomersen may lead to a major life threatening interaction when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Mipomersen may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause... |
DB00186 | DB01181 | 905 | 1,532 | [
"DDInter1092",
"DDInter906"
] | Lorazepam | Ifosfamide | Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm. | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
905,
24,
1532
]
],
[
[
905,
21,
28893
],
[
28893,
60,
1532
]
],
[
[
905,
63,
1648
],
[
1648,
24,
1532
]
],
[
[
905,
40,
481
],
[
481,
... | [
[
[
"Lorazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Lorazepam",
"{u} (Compound) causes {v} (Side Effect)",
"Hallucination"
],
[
"Hallucination",
"{u} (Side Effect) i... | Lorazepam (Compound) causes Hallucination (Side Effect) and Hallucination (Side Effect) is caused by Ifosfamide (Compound)
Lorazepam may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00047 | DB01320 | 176 | 651 | [
"DDInter932",
"DDInter783"
] | Insulin glargine | Fosphenytoin | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Moderate | 1 | [
[
[
176,
24,
651
]
],
[
[
176,
24,
362
],
[
362,
1,
651
]
],
[
[
176,
24,
1479
],
[
1479,
23,
651
]
],
[
[
176,
24,
590
],
[
590,
24... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a... |
DB01319 | DB09082 | 34 | 659 | [
"DDInter777",
"DDInter1934"
] | Fosamprenavir | Vilanterol | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
34,
24,
659
]
],
[
[
34,
63,
1220
],
[
1220,
23,
659
]
],
[
[
34,
24,
423
],
[
423,
23,
659
]
],
[
[
34,
64,
175
],
[
175,
23,
... | [
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],... | Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Ciclesonide... |
DB00011 | DB01095 | 1,451 | 671 | [
"DDInter944",
"DDInter769"
] | Interferon alfa-n1 | Fluvastatin | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to r... | Moderate | 1 | [
[
[
1451,
24,
671
]
],
[
[
1451,
24,
788
],
[
788,
40,
671
]
],
[
[
1451,
24,
14
],
[
14,
63,
671
]
],
[
[
1451,
24,
126
],
[
126,
2... | [
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastat... | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin (Compound) resembles Fluvastatin (Compound)
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a modera... |
DB01409 | DB09272 | 1,415 | 412 | [
"DDInter1815",
"DDInter632"
] | Tiotropium | Eluxadoline | Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma.[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.[A180163,L7084,L... | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Moderate | 1 | [
[
[
1415,
24,
412
]
],
[
[
1415,
63,
1594
],
[
1594,
24,
412
]
],
[
[
1415,
24,
830
],
[
830,
24,
412
]
],
[
[
1415,
24,
1536
],
[
1536,
... | [
[
[
"Tiotropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Tiotropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Tiotropium may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Tiotropium may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phe... |
DB01181 | DB12130 | 1,532 | 1,017 | [
"DDInter906",
"DDInter1094"
] | Ifosfamide | Lorlatinib | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
1532,
24,
1017
]
],
[
[
1532,
63,
590
],
[
590,
24,
1017
]
],
[
[
1532,
25,
976
],
[
976,
24,
1017
]
],
[
[
1532,
74,
450
],
[
450,
... | [
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[... | Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Ifosfamide may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib ma... |
DB00439 | DB00446 | 289 | 597 | [
"DDInter341",
"DDInter351"
] | Cerivastatin | Chloramphenicol | On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Cana... | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Moderate | 1 | [
[
[
289,
24,
597
]
],
[
[
289,
24,
466
],
[
466,
62,
597
]
],
[
[
289,
24,
1626
],
[
1626,
63,
597
]
],
[
[
289,
63,
367
],
[
367,
2... | [
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
]
],
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
... | Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Chloramphenicol
Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab... |
DB00388 | DB00422 | 1,636 | 895 | [
"DDInter1453",
"DDInter1189"
] | Phenylephrine | Methylphenidate | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Methylphenidate is a central nervous system stimulant used most commonly in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and for narcolepsy. Also known as the marketed products Ritalin, Concerta, or Biphentin, methylphenidate is used with other treatment modalities (psychological, educational, cogni... | Moderate | 1 | [
[
[
1636,
24,
895
]
],
[
[
1636,
24,
1177
],
[
1177,
40,
895
]
],
[
[
1636,
24,
85
],
[
85,
1,
895
]
],
[
[
1636,
21,
28658
],
[
28658,
... | [
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylphenidate"
]
],
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexmethylphenida... | Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Dexmethylphenidate and Dexmethylphenidate (Compound) resembles Methylphenidate (Compound)
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine (Compound) resembles... |
DB01142 | DB01224 | 1,264 | 623 | [
"DDInter593",
"DDInter1553"
] | Doxepin | Quetiapine | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Moderate | 1 | [
[
[
1264,
24,
623
]
],
[
[
1264,
64,
827
],
[
827,
1,
623
]
],
[
[
1264,
25,
851
],
[
851,
1,
623
]
],
[
[
1264,
63,
1408
],
[
1408,
... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trazodone"
],
[
"Trazodone",
... | Doxepin may lead to a major life threatening interaction when taken with Trazodone and Trazodone (Compound) resembles Quetiapine (Compound)
Doxepin may lead to a major life threatening interaction when taken with Nefazodone and Nefazodone (Compound) resembles Quetiapine (Compound)
Doxepin may cause a moderate interacti... |
DB00283 | DB11632 | 701 | 580 | [
"DDInter395",
"DDInter1343"
] | Clemastine | Opicapone | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Opicapone is a potent, reversible, and peripherally-acting third-generation inhibitor of catechol-o-methyltransferase (COMT), an enzyme involved in the breakdown of various catecholamines including dopamine.[A36938, A203048] Many patients with Parkinson’s disease treated with levodopa plus a dopa decarboxylase (DDC) in... | Moderate | 1 | [
[
[
701,
24,
580
]
],
[
[
701,
24,
104
],
[
104,
24,
580
]
],
[
[
701,
35,
1594
],
[
1594,
24,
580
]
],
[
[
701,
24,
1053
],
[
1053,
... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opicapone"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
... | Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Clemastine (Compound) resembles Doxylamine (Compound) and Clemastine may cause a moderate interaction that co... |
DB00848 | DB01320 | 281 | 651 | [
"DDInter1044",
"DDInter783"
] | Levamisole | Fosphenytoin | Levamisole is an antihelminthic drug that was commonly used for the treatment of parasitic, viral, and bacterial infections. It was manufactured by _Janssen_ and first used in 1969 as an agent to treat worm infestations Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer. Prior to this,... | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Moderate | 1 | [
[
[
281,
24,
651
]
],
[
[
281,
63,
362
],
[
362,
1,
651
]
],
[
[
281,
25,
908
],
[
908,
63,
651
]
],
[
[
281,
24,
259
],
[
259,
63,
... | [
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
... | Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
Levamisole may lead to a major life threatening interaction when taken with Golimumab and Golimumab may cause a moderate interaction that could exacerbate disea... |
DB00215 | DB06589 | 1,230 | 1,250 | [
"DDInter388",
"DDInter1400"
] | Citalopram | Pazopanib | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Major | 2 | [
[
[
1230,
25,
1250
]
],
[
[
1230,
6,
7950
],
[
7950,
45,
1250
]
],
[
[
1230,
18,
5587
],
[
5587,
46,
1250
]
],
[
[
1230,
21,
29264
],
[
29... | [
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
]
],
[
[
"Citalopram",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Pazopani... | Citalopram (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Pazopanib (Compound)
Citalopram (Compound) downregulates SCAND1 (Gene) and SCAND1 (Gene) is upregulated by Pazopanib (Compound)
Citalopram (Compound) causes Rhinorrhoea (Side Effect) and Rhinorrhoea (Side Effect) is caused by Pazopanib (Compound)
C... |
DB00808 | DB11113 | 1,605 | 657 | [
"DDInter916",
"DDInter307"
] | Indapamide | Castor oil | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a n... | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
1605,
24,
657
]
],
[
[
1605,
24,
891
],
[
891,
24,
657
]
],
[
[
1605,
63,
613
],
[
613,
24,
657
]
],
[
[
1605,
40,
811
],
[
811,
... | [
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
... | Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan and Ir... |
DB00486 | DB01100 | 1,614 | 1,568 | [
"DDInter1253",
"DDInter1470"
] | Nabilone | Pimozide | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Moderate | 1 | [
[
[
1614,
24,
1568
]
],
[
[
1614,
63,
78
],
[
78,
40,
1568
]
],
[
[
1614,
21,
29024
],
[
29024,
60,
1568
]
],
[
[
1614,
24,
649
],
[
649,
... | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pimozide"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Droperidol"
],
[
"D... | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Droperidol and Droperidol (Compound) resembles Pimozide (Compound)
Nabilone (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Pimozide (Compound)
Nabilone may cause a moderate interaction that... |
DB04951 | DB06448 | 187 | 171 | [
"DDInter1477",
"DDInter1087"
] | Pirfenidone | Lonafarnib | Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is pro... | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Moderate | 1 | [
[
[
187,
24,
171
]
],
[
[
187,
63,
254
],
[
254,
24,
171
]
],
[
[
187,
24,
850
],
[
850,
63,
171
]
],
[
[
187,
62,
168
],
[
168,
24,... | [
[
[
"Pirfenidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Pirfenidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitisinone"
],
[
... | Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin... |
DB00959 | DB01067 | 1,486 | 959 | [
"DDInter1191",
"DDInter826"
] | Methylprednisolone | Glipizide | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
1486,
24,
959
]
],
[
[
1486,
63,
245
],
[
245,
40,
959
]
],
[
[
1486,
24,
1411
],
[
1411,
1,
959
]
],
[
[
1486,
6,
8374
],
[
8374,
... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"... | Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Gli... |
DB02701 | DB13928 | 1,632 | 1,385 | [
"DDInter1289",
"DDInter1660"
] | Nicotinamide | Semaglutide | An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and pellagra. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake. | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
1632,
24,
1385
]
],
[
[
1632,
24,
637
],
[
637,
24,
1385
]
],
[
[
1632,
63,
1144
],
[
1144,
24,
1385
]
],
[
[
1632,
24,
1412
],
[
1412... | [
[
[
"Nicotinamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Nicotinamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia c... | Nicotinamide may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi and Asparaginase Erwinia chrysanthemi may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Nicotinamide may cause a moderate interaction that could exacer... |
DB08895 | DB12240 | 976 | 110 | [
"DDInter1825",
"DDInter1485"
] | Tofacitinib | Polatuzumab vedotin | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable link... | Major | 2 | [
[
[
976,
25,
110
]
],
[
[
976,
25,
129
],
[
129,
23,
110
]
],
[
[
976,
64,
1419
],
[
1419,
24,
110
]
],
[
[
976,
63,
1593
],
[
1593,
... | [
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide... | Tofacitinib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Polatuzumab vedotin
Tofacitinib may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a mode... |
DB00982 | DB12130 | 1,517 | 1,017 | [
"DDInter991",
"DDInter1094"
] | Isotretinoin | Lorlatinib | Isotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne.[Label] It was most widely marketed under the brand name Accutane, which has since been discontinued. Isotretinoin is associated with major risks in pregnancy and is therefore only available under the iPLEDGE program in... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
1517,
24,
1017
]
],
[
[
1517,
64,
1101
],
[
1101,
23,
1017
]
],
[
[
1517,
63,
175
],
[
175,
24,
1017
]
],
[
[
1517,
24,
861
],
[
861,
... | [
[
[
"Isotretinoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Isotretinoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexaro... | Isotretinoin may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone ma... |
DB00357 | DB06702 | 1,051 | 573 | [
"DDInter71",
"DDInter731"
] | Aminoglutethimide | Fesoterodine | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome. | Moderate | 1 | [
[
[
1051,
24,
573
]
],
[
[
1051,
6,
8374
],
[
8374,
45,
573
]
],
[
[
1051,
21,
28681
],
[
28681,
60,
573
]
],
[
[
1051,
24,
1424
],
[
1424... | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fesoterodine"
]
],
[
[
"Aminoglutethimide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by ... | Aminoglutethimide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fesoterodine (Compound)
Aminoglutethimide (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Fesoterodine (Compound)
Aminoglutethimide may cause a moderate interaction that could exacerbate disea... |
DB00317 | DB01263 | 883 | 859 | [
"DDInter810",
"DDInter1494"
] | Gefitinib | Posaconazole | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Moderate | 1 | [
[
[
883,
24,
859
]
],
[
[
883,
6,
4973
],
[
4973,
45,
859
]
],
[
[
883,
21,
28708
],
[
28708,
60,
859
]
],
[
[
883,
63,
1101
],
[
1101,
... | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Gefitinib",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Gefitinib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Posaconazole (Compound)
Gefitinib (Compound) causes Malaise (Side Effect) and Malaise (Side Effect) is caused by Posaconazole (Compound)
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexaroten... |
DB00307 | DB09073 | 1,101 | 951 | [
"DDInter202",
"DDInter1379"
] | Bexarotene | Palbociclib | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Moderate | 1 | [
[
[
1101,
24,
951
]
],
[
[
1101,
24,
907
],
[
907,
62,
951
]
],
[
[
1101,
23,
271
],
[
271,
23,
951
]
],
[
[
1101,
24,
479
],
[
479,
... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doravirine"
],
[
... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Palbociclib
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegro... |
DB01095 | DB01229 | 671 | 973 | [
"DDInter769",
"DDInter1377"
] | Fluvastatin | Paclitaxel | Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to r... | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Moderate | 1 | [
[
[
671,
24,
973
]
],
[
[
671,
24,
310
],
[
310,
63,
973
]
],
[
[
671,
6,
7524
],
[
7524,
45,
973
]
],
[
[
671,
7,
2903
],
[
2903,
4... | [
[
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[... | Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Fluvastatin (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Paclitaxel (Compound)
Fluvastatin (C... |
DB00350 | DB01142 | 1,214 | 1,264 | [
"DDInter1226",
"DDInter593"
] | Minoxidil | Doxepin | A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
1214,
24,
1264
]
],
[
[
1214,
24,
508
],
[
508,
24,
1264
]
],
[
[
1214,
24,
1405
],
[
1405,
25,
1264
]
],
[
[
1214,
24,
1191
],
[
1191... | [
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"P... | Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cycloben... |
DB01232 | DB11730 | 1,327 | 351 | [
"DDInter1640",
"DDInter1588"
] | Saquinavir | Ribociclib | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
1327,
25,
351
]
],
[
[
1327,
24,
466
],
[
466,
62,
351
]
],
[
[
1327,
62,
112
],
[
112,
23,
351
]
],
[
[
1327,
25,
283
],
[
283,
... | [
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Daroluta... | Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Saquinavir may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Met... |
DB00069 | DB00352 | 367 | 482 | [
"DDInter946",
"DDInter1814"
] | Interferon alfacon-1 | Tioguanine | Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional am... | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Moderate | 1 | [
[
[
367,
24,
482
]
],
[
[
367,
24,
1439
],
[
1439,
63,
482
]
],
[
[
367,
64,
1648
],
[
1648,
24,
482
]
],
[
[
367,
63,
912
],
[
912,
... | [
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimu... | Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab and Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine
Interferon alfacon-1 may lead to a major life threatening interaction when taken with Aldesleukin and ... |
DB00710 | DB00994 | 1,199 | 361 | [
"DDInter897",
"DDInter1277"
] | Ibandronate | Neomycin | Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to [zoledronic acid], [minodronic acid], and [risedronic acid].[A203111,A203138] It is used to prevent and treat postmenopausal osteoporosis.[L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatm... | Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of _Streptomyces fradiae_. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as [framycetin], is the most active component of the complex and neomycin C is the isomer o... | Moderate | 1 | [
[
[
1199,
24,
361
]
],
[
[
1199,
21,
28722
],
[
28722,
60,
361
]
],
[
[
1199,
24,
1132
],
[
1132,
24,
361
]
],
[
[
1199,
40,
1485
],
[
148... | [
[
[
"Ibandronate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neomycin"
]
],
[
[
"Ibandronate",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by ... | Ibandronate (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Neomycin (Compound)
Ibandronate may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Neomycin
Iban... |
DB00322 | DB00853 | 141 | 1,686 | [
"DDInter742",
"DDInter1762"
] | Floxuridine | Temozolomide | An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been... | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alky... | Moderate | 1 | [
[
[
141,
24,
1686
]
],
[
[
141,
21,
28903
],
[
28903,
60,
1686
]
],
[
[
141,
23,
945
],
[
945,
62,
1686
]
],
[
[
141,
23,
1467
],
[
1467,
... | [
[
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Temozolomide"
]
],
[
[
"Floxuridine",
"{u} (Compound) causes {v} (Side Effect)",
"Dry skin"
],
[
"Dry skin",
"{u} (Side Effect) is ca... | Floxuridine (Compound) causes Dry skin (Side Effect) and Dry skin (Side Effect) is caused by Temozolomide (Compound)
Floxuridine may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Temoz... |
DB00059 | DB09045 | 1,560 | 52 | [
"DDInter1404",
"DDInter607"
] | Pegaspargase | Dulaglutide | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
1560,
24,
52
]
],
[
[
1560,
24,
170
],
[
170,
23,
52
]
],
[
[
1560,
24,
609
],
[
609,
24,
52
]
],
[
[
1560,
24,
517
],
[
517,
63... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin a... |
DB01156 | DB09054 | 593 | 384 | [
"DDInter252",
"DDInter905"
] | Bupropion | Idelalisib | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
593,
24,
384
]
],
[
[
593,
64,
222
],
[
222,
23,
384
]
],
[
[
593,
25,
318
],
[
318,
23,
384
]
],
[
[
593,
24,
1627
],
[
1627,
6... | [
[
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine... | Bupropion may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Bupropion may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may cause a minor inter... |
DB01168 | DB06707 | 1,053 | 584 | [
"DDInter1526",
"DDInter1060"
] | Procarbazine | Levonordefrin | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Levonordefrin acts as a topical nasal decongestant and vasoconstrictor, most often used in dentistry. | Moderate | 1 | [
[
[
1053,
24,
584
]
],
[
[
1053,
25,
1191
],
[
1191,
40,
584
]
],
[
[
1053,
64,
817
],
[
817,
40,
584
]
],
[
[
1053,
24,
1354
],
[
1354,
... | [
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levonordefrin"
]
],
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levodopa"
],
[
"Levod... | Procarbazine may lead to a major life threatening interaction when taken with Levodopa and Levodopa (Compound) resembles Levonordefrin (Compound)
Procarbazine may lead to a major life threatening interaction when taken with Dopamine and Dopamine (Compound) resembles Levonordefrin (Compound)
Procarbazine may cause a mod... |
DB00569 | DB01294 | 553 | 266 | [
"DDInter775",
"DDInter215"
] | Fondaparinux | Bismuth subsalicylate | Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in he... | Bismuth subsalicylate is an antacid and anti-diarrheal agent. Exhibiting antibacterial and gastroprotective properties, bismuth subsalicylate is an insoluble salt of [salicylic acid] linked to trivalent [bismuth cation]. Each molecule of bismuth subsalicylate contains 58% bismuth and 42% salicylate by weight. Bismuth s... | Moderate | 1 | [
[
[
553,
24,
266
]
],
[
[
553,
21,
28643
],
[
28643,
60,
266
]
],
[
[
553,
25,
1347
],
[
1347,
24,
266
]
],
[
[
553,
25,
235
],
[
235,
... | [
[
[
"Fondaparinux",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bismuth subsalicylate"
]
],
[
[
"Fondaparinux",
"{u} (Compound) causes {v} (Side Effect)",
"Infection"
],
[
"Infection",
"{u} (Side ... | Fondaparinux (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Bismuth subsalicylate (Compound)
Fondaparinux may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Bismu... |
DB00660 | DB01041 | 1,470 | 770 | [
"DDInter1163",
"DDInter1789"
] | Metaxalone | Thalidomide | Metaxalone is a moderate to strong muscle relaxant used in the symptomatic treatment of musculoskeletal pain caused by strains, sprains, and other musculoskeletal conditions. It is marketed by King Pharmaceuticals under the brand name Skelaxin®. Its main mechanism of action is thought to involve general central nervous... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
1470,
24,
770
]
],
[
[
1470,
21,
28921
],
[
28921,
60,
770
]
],
[
[
1470,
24,
849
],
[
849,
63,
770
]
],
[
[
1470,
63,
1614
],
[
1614,... | [
[
[
"Metaxalone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Metaxalone",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is cau... | Metaxalone (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Thalidomide (Compound)
Metaxalone may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Thalid... |
DB00831 | DB04843 | 1,178 | 1,511 | [
"DDInter1866",
"DDInter1149"
] | Trifluoperazine | Mepenzolate | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
1178,
24,
1511
]
],
[
[
1178,
24,
537
],
[
537,
24,
1511
]
],
[
[
1178,
63,
262
],
[
262,
24,
1511
]
],
[
[
1178,
24,
649
],
[
649,
... | [
[
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
]... | Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Clidinium an... |
DB00252 | DB01278 | 362 | 1,021 | [
"DDInter1460",
"DDInter1506"
] | Phenytoin | Pramlintide | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
362,
24,
1021
]
],
[
[
362,
63,
1560
],
[
1560,
24,
1021
]
],
[
[
362,
24,
891
],
[
891,
24,
1021
]
],
[
[
362,
25,
1019
],
[
1019,
... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
... | Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and P... |
DB01177 | DB06168 | 77 | 1,531 | [
"DDInter904",
"DDInter281"
] | Idarubicin | Canakinumab | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Moderate | 1 | [
[
[
77,
24,
1531
]
],
[
[
77,
63,
1461
],
[
1461,
23,
1531
]
],
[
[
77,
63,
377
],
[
377,
24,
1531
]
],
[
[
77,
24,
1270
],
[
1270,
... | [
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Canakinumab
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomycin ... |
DB01142 | DB01193 | 1,264 | 819 | [
"DDInter593",
"DDInter12"
] | Doxepin | Acebutolol | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. | Moderate | 1 | [
[
[
1264,
24,
819
]
],
[
[
1264,
63,
887
],
[
887,
1,
819
]
],
[
[
1264,
6,
12523
],
[
12523,
45,
819
]
],
[
[
1264,
21,
28762
],
[
28762,... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pindolol"
],
[
"Pin... | Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Pindolol and Pindolol (Compound) resembles Acebutolol (Compound)
Doxepin (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Acebutolol (Compound)
Doxepin (Compound) causes Headache (Side Effect) and Headache (Side Effect) ... |
DB00427 | DB04837 | 1,233 | 649 | [
"DDInter1879",
"DDInter407"
] | Triprolidine | Clofedanol | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Moderate | 1 | [
[
[
1233,
24,
649
]
],
[
[
1233,
24,
1376
],
[
1376,
24,
649
]
],
[
[
1233,
63,
21
],
[
21,
24,
649
]
],
[
[
1233,
25,
675
],
[
675,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Amitrip... |
DB00436 | DB01129 | 323 | 379 | [
"DDInter179",
"DDInter1559"
] | Bendroflumethiazide | Rabeprazole | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) | Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion. | Moderate | 1 | [
[
[
323,
24,
379
]
],
[
[
323,
24,
1215
],
[
1215,
40,
379
]
],
[
[
323,
24,
660
],
[
660,
1,
379
]
],
[
[
323,
63,
837
],
[
837,
1,... | [
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansopra... | Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole (Compound) resembles Rabeprazole (Compound)
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole (Compound) resem... |
DB04946 | DB11837 | 924 | 1,297 | [
"DDInter907",
"DDInter1351"
] | Iloperidone | Osilodrostat | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Major | 2 | [
[
[
924,
25,
1297
]
],
[
[
924,
62,
112
],
[
112,
23,
1297
]
],
[
[
924,
63,
222
],
[
222,
23,
1297
]
],
[
[
924,
64,
401
],
[
401,
... | [
[
[
"Iloperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
]
],
[
[
"Iloperidone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metro... | Iloperidone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and... |
DB01075 | DB01197 | 1,376 | 1,603 | [
"DDInter569",
"DDInter292"
] | Diphenhydramine | Captopril | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment ... | Moderate | 1 | [
[
[
1376,
24,
1603
]
],
[
[
1376,
63,
610
],
[
610,
1,
1603
]
],
[
[
1376,
6,
12523
],
[
12523,
45,
1603
]
],
[
[
1376,
21,
28921
],
[
289... | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Captopril"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
],
... | Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril (Compound) resembles Captopril (Compound)
Diphenhydramine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Captopril (Compound)
Diphenhydramine (Compound) causes Dizziness (Side Effect) an... |
DB00006 | DB00031 | 942 | 20 | [
"DDInter217",
"DDInter1764"
] | Bivalirudin | Tenecteplase | Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important t... | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Major | 2 | [
[
[
942,
25,
20
]
],
[
[
942,
23,
1631
],
[
1631,
62,
20
]
],
[
[
942,
24,
758
],
[
758,
63,
20
]
],
[
[
942,
25,
477
],
[
477,
63,
... | [
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
]
],
[
[
"Bivalirudin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
],
[
"Turmeric",... | Bivalirudin may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Tenecteplase
Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine and Fluoxetine... |
DB05812 | DB12267 | 1,374 | 1,476 | [
"DDInter8",
"DDInter233"
] | Abiraterone | Brigatinib | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
1374,
24,
1476
]
],
[
[
1374,
24,
1612
],
[
1612,
23,
1476
]
],
[
[
1374,
23,
1135
],
[
1135,
23,
1476
]
],
[
[
1374,
24,
800
],
[
800... | [
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[... | Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Abiraterone may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxeg... |
DB00539 | DB01015 | 11 | 1,247 | [
"DDInter1837",
"DDInter1724"
] | Toremifene | Sulfamethoxazole | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps i... | Minor | 0 | [
[
[
11,
23,
1247
]
],
[
[
11,
6,
8374
],
[
8374,
45,
1247
]
],
[
[
11,
18,
10375
],
[
10375,
57,
1247
]
],
[
[
11,
21,
29027
],
[
29027,
... | [
[
[
"Toremifene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
]
],
[
[
"Toremifene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Toremifene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sulfamethoxazole (Compound)
Toremifene (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Sulfamethoxazole (Compound)
Toremifene (Compound) causes Ataxia (Side Effect) and Ataxia (Side Effect) is caused by Sulfamethoxazole... |
DB00842 | DB08900 | 686 | 1,162 | [
"DDInter1359",
"DDInter1753"
] | Oxazepam | Teduglutide | Oxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and anxiety disorders. Oxazepam, like related 3-hydroxybenzodiazepine [lorazepam], is considered less susceptible to pharmacokinetic variability based on patient-specific factors (e.g. age, liver disease) - this feat... | Teduglutide is a glucagon-like peptide-2 (GLP-2) analogue. It is made up of 33 amino acids and is manufactured using a strain of Escherichia coli modified by recombinant DNA technology. Teduglutide differs from GLP-2 by one amino acid (alanine is substituted by glycine). The significance of this substitution is that te... | Moderate | 1 | [
[
[
686,
24,
1162
]
],
[
[
686,
40,
1119
],
[
1119,
24,
1162
]
],
[
[
686,
1,
905
],
[
905,
24,
1162
]
],
[
[
686,
40,
1119
],
[
1119,
... | [
[
[
"Oxazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teduglutide"
]
],
[
[
"Oxazepam",
"{u} (Compound) resembles {v} (Compound)",
"Chlordiazepoxide"
],
[
"Chlordiazepoxide",
"{u} may cause ... | Oxazepam (Compound) resembles Chlordiazepoxide (Compound) and Chlordiazepoxide may cause a moderate interaction that could exacerbate diseases when taken with Teduglutide
Oxazepam (Compound) resembles Lorazepam (Compound) and Lorazepam may cause a moderate interaction that could exacerbate diseases when taken with Tedu... |
DB00514 | DB01186 | 506 | 107 | [
"DDInter527",
"DDInter1430"
] | Dextromethorphan | Pergolide | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinson’s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic tr... | Moderate | 1 | [
[
[
506,
24,
107
]
],
[
[
506,
6,
12523
],
[
12523,
45,
107
]
],
[
[
506,
21,
28757
],
[
28757,
60,
107
]
],
[
[
506,
24,
832
],
[
832,
... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pergolide"
]
],
[
[
"Dextromethorphan",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (... | Dextromethorphan (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pergolide (Compound)
Dextromethorphan (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Pergolide (Compound)
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Tri... |
DB00553 | DB00902 | 92 | 104 | [
"DDInter1177",
"DDInter1168"
] | Methoxsalen | Methdilazine | A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation. | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
92,
24,
104
]
],
[
[
92,
24,
820
],
[
820,
1,
104
]
],
[
[
92,
63,
508
],
[
508,
1,
104
]
],
[
[
92,
24,
401
],
[
401,
63,
... | [
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
... | Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Methdilazine (Compound)
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Methdilazine (Comp... |
DB01254 | DB09065 | 1,213 | 760 | [
"DDInter484",
"DDInter424"
] | Dasatinib | Cobicistat | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Major | 2 | [
[
[
1213,
25,
760
]
],
[
[
1213,
62,
479
],
[
479,
23,
760
]
],
[
[
1213,
23,
271
],
[
271,
23,
760
]
],
[
[
1213,
64,
1230
],
[
1230,
... | [
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Dasatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"Donepezil",
... | Dasatinib may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Dasatinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may c... |
DB00420 | DB11730 | 508 | 351 | [
"DDInter1532",
"DDInter1588"
] | Promazine | Ribociclib | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
508,
25,
351
]
],
[
[
508,
23,
112
],
[
112,
23,
351
]
],
[
[
508,
24,
222
],
[
222,
23,
351
]
],
[
[
508,
24,
355
],
[
355,
24,... | [
[
[
"Promazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Promazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazo... | Promazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibut... |
DB00308 | DB01169 | 347 | 57 | [
"DDInter901",
"DDInter120"
] | Ibutilide | Arsenic trioxide | Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR). | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Major | 2 | [
[
[
347,
25,
57
]
],
[
[
347,
23,
112
],
[
112,
23,
57
]
],
[
[
347,
24,
603
],
[
603,
63,
57
]
],
[
[
347,
24,
480
],
[
480,
24,
... | [
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Ibutilide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metro... | Ibutilide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Arsenic trioxide
Ibutilide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citra... |
DB00204 | DB08881 | 228 | 868 | [
"DDInter580",
"DDInter1925"
] | Dofetilide | Vemurafenib | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
228,
25,
868
]
],
[
[
228,
6,
8374
],
[
8374,
45,
868
]
],
[
[
228,
21,
28714
],
[
28714,
60,
868
]
],
[
[
228,
25,
608
],
[
608,
... | [
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Dofetilide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vemura... | Dofetilide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Dofetilide (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Vemurafenib (Compound)
Dofetilide may lead to a major life threatening interaction when taken with Lidocaine and Lidocaine may cause ... |
DB01227 | DB06616 | 1,301 | 594 | [
"DDInter1043",
"DDInter224"
] | Levacetylmethadol | Bosutinib | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well... | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Major | 2 | [
[
[
1301,
25,
594
]
],
[
[
1301,
6,
8374
],
[
8374,
45,
594
]
],
[
[
1301,
62,
112
],
[
112,
23,
594
]
],
[
[
1301,
63,
1559
],
[
1559,
... | [
[
[
"Levacetylmethadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
]
],
[
[
"Levacetylmethadol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Levacetylmethadol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Levacetylmethadol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bosutinib
Leva... |
DB09112 | DB09237 | 1,455 | 1,586 | [
"DDInter1306",
"DDInter1045"
] | Nitrous acid | Levamlodipine | Nitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning. It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system. There is also research to investigate its applica... | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlod... | Moderate | 1 | [
[
[
1455,
24,
1586
]
],
[
[
1455,
63,
549
],
[
549,
24,
1586
]
],
[
[
1455,
24,
433
],
[
433,
63,
1586
]
],
[
[
1455,
63,
549
],
[
549,
... | [
[
[
"Nitrous acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
]
],
[
[
"Nitrous acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]... | Nitrous acid may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Nitrous acid may cause a moderate interaction that could exacerbate diseases when taken with Ertuglif... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.